IDH1 and central nervous system cancer: Following early data showing Ivosidenib Suppressed tumor 2-HG in glioma [156], Vorasidenib, a dual IDH1/2 inhibitor with improved brain penetrance, was evaluated in a Phase I study (NCT03343197).